US FDA approves Noven’s schizophrenia treatment administered through a once-daily transdermal delivery system, able to release the antipsychotic drug for 24 hours.
MedPharm expands its US Center of Excellence in Durham, North Carolina, in response to increasing demand for its topical and transdermal formulation development, and performance testing services.
Ahead of the CPhI Worldwide in Madrid next week, Nemaura announced that it would be showcasing its newly developed 48-hour diclofenac transdermal patch and would be linking up with an unnamed global pharma company to develop three new products.
Acino has agreed to sell its transdermal delivery patch business Luye Pharma Group in a deal that will include its manufacturing site in Miesbach, Germany.
A transdermal patch technology developed by 3M Drug Delivery could lead to new injection free, compliance-boosting treatments for postmenopausal osteoporosis.
Medingo’s insulin dispensing patch has been approved by the US Food and Drug Administration (FDA), sending shares in its parent company soaring to a 12 month high.
Alpharma has licensed an investigational transdermal bupivacaine patch from Durect for an initial $20m, with further payments based on reaching developmental milestones.
Shire and Noven have voluntarily withdrawn batches of the ADHD drug Daytrana for the second time in 12 months due to ongoing problems with the product’s release liner.
A new study has demonstrated for the first that microneedle
technology is able to overcome some of the barriers preventing the
transdermal administration of drugs with low bioavailability.
Shire Pharmaceuticals has acquired exclusive development rights to
a new transdermal patch product for Attention-Deficit/Hyperactivity
Disorder (ADHD), adding a further novel product to its ADHD
portfolio.
A combination of new drugs, new patient needs and new technologies
is likely to fuel steady growth in the transdermal/transmucosal
drug delivery market during the years to 2010.
Novel transdermal patch products for two protein drugs could be on
the horizon as Altea Therapeutics announces research agreements
with two 'large' pharmaceutical companies.
A novel drug delivery system that allows hospital patients to
self-administer pain relief medication without an intravenous line
could be available in the US within six months, pending final Food
and Drug Administration (FDA) approval.
Australian drug delivery company Acrux, which specialises in
administering medicines through the skin, has reported clinical
results of a contraceptive for women in the form of a spray,
reports Phil Taylor.
TransPharma Medical has entered into collaboration with Teva
Pharmaceutical to develop transdermal drug delivery systems. The
deal aims to research and develop transdermal delivery of
therapeutic drugs such as high molecular weight...
Australian drug delivery company Acrux is hoping to raise A$30
million (€18m) in a float on the Australian Stock Exchange to
support the development of its novel transdermal technology that
does not require the use of adhesive patches...
